Literature DB >> 23496083

Application of high-throughput affinity-selection mass spectrometry for screening of chemical compound libraries in lead discovery.

Hartmut Zehender1, Lorenz M Mayr.   

Abstract

High-throughput screening of chemical libraries for compounds that interfere with a particular molecular target is among the most powerful methodologies applied in lead discovery at present. In this review, the authors describe a label-free, homogeneous, affinity-selection-based technology developed at Novartis, termed SpeedScreen, which is compared with similar technologies used for high-throughput screening in the pharmaceutical and biotechnology industries. The focus at present of SpeedScreen is twofold: first, this technology is applied to orphan genomic targets and to those targets that are non-tractable by a functional assay; second, this technology is applied complementary to the well-established traditional methodologies for the screening of molecular targets. In summary, the authors discuss the value of affinity-selection-based high-throughput screening as a complementary technology to the common functional screening platforms and the benefits as well as the limitations of this new technology are outlined.

Year:  2007        PMID: 23496083     DOI: 10.1517/17460441.2.2.285

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  2 in total

1.  HAMS: High-Affinity Mass Spectrometry Screening. A High-Throughput Screening Method for Identifying the Tightest-Binding Lead Compounds for Target Proteins with No False Positive Identifications.

Authors:  Kasun P Imaduwage; Eden P Go; Zhikai Zhu; Heather Desaire
Journal:  J Am Soc Mass Spectrom       Date:  2016-09-06       Impact factor: 3.109

2.  High-Throughput Assessment of Structural Continuity in Biologics.

Authors:  Caterina Musetti; Mark F Bean; Geoffrey T Quinque; Christopher Kwiatkowski; Lawrence M Szewczuk; John Baldoni; Matthew A Zajac
Journal:  Anal Chem       Date:  2018-02-08       Impact factor: 6.986

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.